WEREWOLF THERAPEUTICS INC (HOWL)
US95075A1079 - Common Stock
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Company to present an update of its ongoing monotherapy and combination Phase 1/1b study of WTX-124 in advanced or metastatic solid tumors WATERTOWN,...
Werewolf Therapeutics Enters Oversold Territory (HOWL)
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
WTX-518, a conditionally activated IL-18 INDUKINETM molecule that resists suppression by IL-18BP, led to complete tumor regressions in preclinical models
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
PREDATOR protein engineering technology allows for the expansion of INDUKINE™ molecules beyond oncology targets into new applications across a range of immunology targets, including inflammatory bowel disease
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
PREDATOR protein engineering technology allows for the expansion of INDUKINE™ molecules beyond oncology targets into new applications across a range of...
HOWL Stock Earnings: Werewolf Therapeutics Beats EPS, Misses Revenue for Q4 2023
HOWL stock results show that Werewolf Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
HOWL Stock Earnings: Werewolf Therapeutics Beats EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Werewolf Therapeutics (NASDAQ:HOWL) just reported results for the fourth quarte...
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
– Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first half of 2024 – ...
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the publication of abstracts for upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California.
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
- Prioritizing development of wholly owned clinical assets, WTX-124 and WTX-330; key updates from both INDUKINETM programs anticipated in 2024 - ...
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative...
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference
WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative...
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
– Preliminary data from the WTX-124 monotherapy dose-escalation arm of the ongoing Phase 1/1b clinical trial provide compelling early evidence of...
Delta Air Lines Layoffs 2023: What to Know About the Latest DAL Job Cuts
Delta Air Lines layoffs have the air travel company announcing minor adjustments to its corporate and management positions.
CVNA Stock Alert: What Analysts Are Saying After Carvana’s Q3 Earnings
Carvana stock is on the move as analysts weigh in on CVNA shares following the release of the company's latest earnings report.
Why Is Werewolf Therapeutics (HOWL) Stock Up 20% Today?
Werewolf Therapeutics stock is taking off with heavy trading of HOWL shares after posting preliminary data from a clinical trial.
Werewolf Therapeutics stock jumps on data for cancer drug
Shares of Werewolf Therapeutics (HOWL) surge 34% as early-stage clinical trials show promising results for its cancer candidate WTX-124 in solid tumors.
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
Preliminary data on WTX-124 provide compelling early evidence of dose-dependent biomarker and antitumor activity in patients with advanced or metastatic...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a hot topic on Thursday and we're checking out all of the biggest ones worth watching this morning!
Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
Interim, first-in-human clinical results from initial monotherapy dose-escalation cohorts in ongoing Phase 1/1b study of WTX-124 including safety and...